Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 27, 2008
Business Overview: IRIDEX is a provider of therapeutic laser systems for ophthalmology and aesthetics. The company operates two reportable segments: Ophthalmology and Aesthetics. The Aesthetics segment was acquired from Laserscope (a subsidiary of American Medical Systems) in January 2007.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 27, 2008 |
Nine Months Ended Sep 27, 2008 |
Nine Months Ended Sep 29, 2007 |
|---|---|---|---|
| Revenues | $11,987 | $36,383 | $41,390 |
| Gross Profit | $4,990 | $15,126 | $17,978 |
| Gross Margin | 41.6% | 41.6% | 43.4% |
| Net Loss | $(249) | $(867) | $(6,501) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.10) | $(0.80) |
| Cash and Cash Equivalents | $2,974 | Balance Sheet Data (Sep 27, 2008) | |
| Total Debt (Bank Line of Credit) | $6,000 | Balance Sheet Data (Sep 27, 2008) | |
| Working Capital | $9,409 | Calculated: Current Assets ($26,980) - Current Liab ($17,571) |
Cash Flow (Nine Months Ended Sep 27, 2008):
- Net cash used in operating activities: $(2,564) thousand
- Net cash used in investing activities: $(42) thousand
- Net cash used in financing activities: $(79) thousand
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 11.7% in the quarter and 12.1% for the nine-month period compared to 2007.
- Ophthalmology: Revenue increased slightly (4.0% in Q3, 1.9% for nine months), driven by recurring revenues (disposables and service).
- Aesthetics: Revenue decreased significantly (33.3% in Q3, 30.4% for nine months) due to market softening, economic uncertainty, and a strong U.S. dollar impacting international sales.
- Profitability Improvement: While the company remains unprofitable, the net loss narrowed significantly year-over-year. The nine-month net loss decreased from $6.5 million in 2007 to $0.9 million in 2008.
- Expense Reduction: Operating expenses decreased substantially due to headcount reductions. Selling, General, and Administrative (SG&A) expenses dropped 38.6% for the nine-month period.
- Legal Settlement: The company received $0.8 million in the second quarter of 2008 from a patent infringement settlement with Synergetics, recorded as a gain in the nine-month period.
- Liquidity Position: Cash and cash equivalents decreased from $5.8 million at year-end 2007 to $3.0 million at September 27, 2008. The company utilized cash to repay the full outstanding liability to AMS ($4.8 million).
Guidance, Outlook, Risks, and Contingencies
- Going Concern Uncertainty: The independent auditor's report for the fiscal year ended December 29, 2007, included a qualification stating substantial doubt about the Company's ability to continue as a going concern due to operating losses and debt covenant failures. Management believes current cash and the credit facility provide sufficient liquidity for the next 12 months, but notes significant risk in achieving the operating plan.
- Debt Covenants: The company has a credit facility with Wells Fargo Bank. In August 2008, the company was not in compliance with debt service covenants but obtained a waiver and was compliant in September 2008. Failure to meet covenants could result in the bank declaring all obligations due.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 27, 2008, due to a material weakness regarding inadequate staffing levels in the finance function. Remediation efforts are underway.
- Tax Contingency: The company identified a probable underpayment of withholding tax regarding overseas subsidiaries. The estimated liability ranges from $644,000 to $1,877,000. The company expects indemnification from AMS and has recorded an asset for the recoverable amount.
- Market Risks: The company faces risks from worldwide economic slowdowns, which have already impacted the discretionary aesthetics market. Additionally, the expiration of a key "Connector Patent" in 2009 poses a risk to recurring revenue from disposable laser probes.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain compliance with Wells Fargo Bank covenants, specifically regarding debt service coverage, given the recent waiver history.
- Aesthetics Segment Turnaround: Assess the effectiveness of the rebuilt U.S. aesthetics sales force and whether revenue declines in this segment have stabilized.
- Internal Control Remediation: Monitor progress in hiring finance staff and remediation of the material weakness in internal controls to ensure future financial reporting reliability.
- Cash Burn Rate: Track operating cash flow usage to ensure the $3.0 million cash balance and credit facility are sufficient to fund operations for the full 12-month horizon.
- Patent Expiration Impact: Evaluate the potential impact on recurring revenue streams as the "Connector Patent" approaches expiration in 2009.